SGHT · Sight Sciences, Inc.

The thesis

Sight Sciences is building TearCare, its dry-eye treatment, into a second revenue line that insurers now pay for, while its OMNI glaucoma devices keep growing. The third-quarter report, expected around 5 November 2026, settles it: dry-eye sales either support the raised $88–92 million 2026 revenue guidance or they do not.

The shares closed at $8.47 on 8 October 2026, 9.5% below the $9.36 52-week closing high and up 58.6% over three months, according to adjusted daily closes. They had closed at $8.92 on 5 October 2026 and $8.56 on 6 October 2026, after SEC Form 4 filings showed five executives selling shares on 1 October 2026 and 2 October 2026. No new results, guidance or SEC filings from the company have appeared since the OMNI Ultra launch on 1 October 2026.

The narrative is maturing: the dry-eye and OMNI Ultra stories are well known, and since the 1 October 2026 launch the only news has been executive share sales while the price has eased below the 52-week high. The case holds while the shares close above $7.80 and dry-eye revenue keeps rising from quarter to quarter.

Bullish and bearish views on Sight Sciences, Inc.

The bull case on Sight Sciences, Inc. (SGHT), in brief: Dry-eye treatment now has payer support. The bear case: The price sits above analyst targets.

Bull case

• Dry-eye treatment now has payer support. At the second quarter, 14.5 million patient lives had access to appropriate TearCare reimbursement, up from 10.4 million, after insurer fee schedules aligned with updated Medicare pricing for CPT (Current Procedural Terminology) code 0563T (company release, 5 August 2026).
• Dry-eye revenue nearly doubled in a quarter. Interventional Dry Eye revenue was $2.7 million in the second quarter, up 704% year on year and up from $1.4 million in the first quarter (company releases, 6 May 2026 and 5 August 2026).
• Guidance has been raised twice in 2026. The revenue range moved to $83.0–89.0 million at the first-quarter report on 6 May 2026 and to $88–92 million on 5 August 2026, implying 14–19% growth, with dry eye guided to $9–11 million.
• Losses are narrowing quickly. The second-quarter net loss was $4.4 million, 63% smaller than a year earlier, cash use was $5.2 million and cash stood at $79.8 million (company release, 5 August 2026).
• A new glaucoma device reaches surgeons. OMNI Ultra received FDA (Food and Drug Administration) 510(k) clearance on 4 August 2026, became commercially available on 1 October 2026 and has its full debut at the American Academy of Ophthalmology (AAO) meeting in New Orleans on 9 October to 12 October 2026 (company release, 1 October 2026).
• A patent judgment against Alcon stands for now. A Delaware federal court order on 27 March 2026 upheld the finding that Alcon's Hydrus Microstent willfully infringed three Sight Sciences patents, with $34 million in damages plus supplemental damages and interest and a 10% ongoing royalty on Hydrus revenue through 10 November 2028 (company 8-K, 30 March 2026).

Bear case

• The price sits above analyst targets. MarketBeat listed a $7.88 consensus target from eight analysts in early October 2026, and UBS's target is $8.00 after a raise on 6 August 2026. Both sit below the $8.47 close on 8 October 2026.
• the chief financial officer, chief operating officer and an executive vice president sold 7,208, 25,260 and 2,988 shares at a weighted $8.853 on 2 October 2026 (SEC Form 4 filings via MarketBeat and Kalkine Media). Kalkine Media reported the 2 October 2026 sales covered tax on vesting restricted stock units.
• Dry eye is still a small business. Dry-eye revenue of $2.7 million was 12% of second-quarter revenue of $23.4 million; Interventional Glaucoma supplied $20.7 million (company release, 5 August 2026).
• Glaucoma growth is guided to slow. The company guided Interventional Glaucoma revenue to $79–81 million for 2026, 4–7% growth, so the raised total depends heavily on dry eye (company release, 5 August 2026).
• The company still loses money. The $4.4 million second-quarter net loss means cash, not profit, funds the dry-eye build-out (company release, 5 August 2026).

Price setup

The shares closed at $8.47 on 8 October 2026, 9.5% under the $9.36 52-week closing high, after a 58.6% rise over three months (adjusted daily closes). The 14-day relative strength index, a momentum gauge where readings above 70 usually mark overbought conditions, stood at 57.1 on 8 October 2026, so the run has cooled from its peak without breaking.

The executive sales at $9.05 and $8.853 sit just under the high and mark where selling met the advance. Below the price, $7.80 is the level that matters: it lies under the $7.88 consensus target and UBS's $8.00 target, so a close there would return the shares inside the range analysts have priced. Crowding is moderate: the OMNI Ultra launch day on 1 October 2026 traded at 5.0 times average volume (StockTitan), executives sold into strength, and an earnings report lands inside four weeks.

Catalysts, next 30 days

• 9 October to 12 October 2026: AAO annual meeting in New Orleans, the full debut of the OMNI Ultra Surgical System. Surgeon response at the largest US eye-surgery meeting is the first read on demand for the new glaucoma device.
• ~5 November 2026, est.: Third-quarter 2026 results. The company has not yet announced the date; it reported the third quarter of 2024 on 7 November 2024. The report shows whether dry-eye revenue keeps climbing from $2.7 million and whether the $88–92 million range holds.

Elapsed catalysts

• Date not set: Alcon's appeal of the 27 March 2026 Hydrus judgment. A ruling would change the value of the damages award and the 10% royalty. (passed 199d ago)

What would change the view

The case breaks if third-quarter dry-eye revenue comes in flat or below the second quarter's $2.7 million, or if the company cuts its $9–11 million dry-eye range. That would show reimbursement access is not turning into procedures. Interventional Glaucoma growth below the guided 4–7% pace, quarterly cash use well above $5.2 million, or an equity offering filed with the SEC would also weaken it.

On price, a daily close below $7.80 would put the shares back under every published analyst target cited here and erase a large part of the autumn advance. The case strengthens if dry-eye revenue rises again in the third quarter and the company reaffirms or raises the $88–92 million revenue range.

What it trades with

Sight Sciences trades as a small-cap, money-losing medical-device company, so broad small-cap risk appetite and interest-rate moves are likely to move it alongside company news. Glaukos is the closest listed glaucoma-device peer, and Alcon is both a competitor and the counterparty in the Hydrus patent case. The dry-eye part of the story turns on payer decisions about CPT code 0563T, which ties the shares to Medicare contractor and commercial insurer policy more than to any peer's results.